Review
Open access
Sep 2026
Daraxonrasib Treatment in RAS-Mutated Pancreatic Cancer: Mechanisms, Clinical Evidence and Future Perspectives
A review explores the pathogenic role of KRAS mutations in pancreatic cancer, traces the development and mechanism of daraxonrasib, evaluates supporting clinical data, and discusses its strengths, limitations, and future positioning in managing RAS-mutated PDAC.
Zhou-Yu Song
· Transactions on Materials, B... · 0 citations